Could ETQ's share price be soon to benefit from their developments with the new UVGI Nightingale Mobile Air Filtration Product.

New UVGI air filtration product

In November 2002, the ETQ announced its new Nightingale UVGI air filtration product, to be produced by a new joint-venture company, UVGI Systems Limited, owned 55% by the Group and 45% by Suvair Limited. This rapid response mobile air filtration unit is capable of killing the MRSA super bug and other airborne pathogens.

The UVGI unit has widespread application where there is need to keep
air free of dangerous live bacteria, viruses, and fungal spores, including
hospitals, schools, cruise liners, aircraft, food processing, and military
applications.

The UVGI unit uses a high intensity Ultra Violet Germicidal Irradiation ('UVGI')
filter, which has been designed to control harmful and dangerous airborne
pathogens, such as Anthrax, Tuberculosis, and Staphylococcus aureus, the
causative agent in MRSA. The filtration system is combined with use of high
intensity Ultra Violet light, which inactivates micro organisms by disrupting
their DNA structure.

Tests of a prototype at the Defence Science Technology Laboratory ('Dstl') at
Porton Down, the centre for excellence for the Ministry of Defence, showed that
the UVGI unit captured and/or destroyed more than 99.9% of Bacillus subtilis
spores, a simulant for Anthrax bacteria.

Since November, second generation units have been developed, which will go on
applications testing at an NHS Trust Hospital in December 2003, following
building completion of its new haematology unit. It is also anticipated the
UVGI unit will shortly go on laboratory testing in the United States with
contractors nominated by the Department of Homeland Security.

Concern seems to be hotting up on the T.V. news that the MRSA super bug is still killing and disabling people visiting or as patients in NH Trust hospitals. It would be surprising if NH Trust hospital do not notice and Buy this product before they get to many expensive law suits for compensation claims.

Definitely a stock that could soon be heading north. Worth buying in but DYOR

L.

RELATED NEWS LINKS

Sky News Sun 28th Sept 03 - NEW ANTIBIOTICS WARNING
BBC World News Thurs 4th December 03 - Hospital infections: Case studies
BBC World News Fri 5th Dec 03 - 'Superbug' crackdown is launched
BBC World News Monday 22nd Dec 03 - Superbugs lurk in intensive care
Sky News Sun 14th Dec 03 - SUPERBUG CARRIED BY PETS
BBC World News Thurs 26th Feb 04 - Superbug deaths increase 15-fold
BBC World News Mon 22nd March 04 - MRSA superbug hits more children
BBC World News Fri 2nd April 04 - Superbug outbreak in cardiac ward
BBC World News Thurs 8th April 04 - NHS faces superbug legal claims
BBC World News Sun 6th June 04 - Government 'complacent' over MRSA
BBC World News Fri 18th June 04 - Superbug deaths 'set to double'
BBC World News Thurs 1st July 04 - Holland's tough line combats MRSA
BBC World News Thurs 1st July 04 - Overcrowded hospitals breed MRSA
ITV.com Fri 9th July 04 - Mother's MRSA nightmare
ITV.com Fri 9th July 04 - 'MRSA superbug has done this to me'
ITV.com Fri 9th July 04 - Precautions you can take against MRSA
Sky News Sun 11th July 04 - WAR DECLARED ON MRSA
BBC UK News Mon 12th July 04 - Drive to fight hospital superbugs

RNS Number:0578B
Energy Technique PLC
21 July 2004


Energy Technique plc
Preliminary Announcement 2004


* #3 million share placing to finance growth of the new high-value divisions

* First sale of UVGI Nightingale system in the USA in July 2004,following
successful completion of testing by the Health Protection Agency

* Diffusion Heating and Cooling sales recovery in third quarter in competitive
market

* Diffusion DX Air Conditioning sales up from #0.8 million to #2.6 million

* Exclusive EU distribution rights obtained for NQ Environmental ultra violet
products to complement the Group's Nightingale UVGI unit

* Exclusive EU distribution rights obtained from Nutech of Canada

Overview
Following a year of extremely difficult operating conditions caused by a sharp
and unexpected downturn in the Group's traditional markets, I am pleased to be
able to report that we have now put in place both the funding and new
distribution agreements needed to develop and grow the new Diffusion Air
Treatment division and Diffusion DX Air Conditioning.

I am pleased to report that a #3 million share placing was completed on 30 April
2004, which has re-financed the Group and will provide the necessary capital
base to fund the planned growth of the Group. In the first quarter of the
current financial year, Diffusion Heating and Cooling continued its recovery.


Current trading and prospects

The group incurred a small loss in the first quarter of the year ending 31 March
2005, due primarily to operating losses incurred by Diffusion Air Treatment:

* Diffusion Heating and Cooling slightly exceeded its expected sales
levels, but only managed to break even, due to a combination of weaker than
expected sales mix and margin. Importantly, Diffusion Heating and Cooling
generated operating profits in both May and June and has good trading
prospects for the second quarter.

* Diffusion DX Air Conditioning operated close to its expected sales and profit
levels and the forward order prospects are excellent.

* The operating losses for Diffusion Air Treatment were lower than expected,
due to a combination of sales below expectations offset by lower operating
costs. The investment in additional resources could not be started until the
proceeds of the #3 million share placing were received in early May, but
investment in development and marketing of the new product ranges is now
proceeding as fast as is feasible.

The Group is now soundly financed, following completion of the #3 million share
placing and the Board is now confident of realising its full potential over the
next 24 months.


Group financial performance in the year ended 31 March 2004

Group sales fell from #11.7 million to #10.8 million and an operating loss after
exceptional items was incurred of #1.472 million.

Diffusion Heating and Cooling sales fell to #8.0 million (2003: #10.9 million),
due to a sharp deterioration in the fan coil market in the first half of 2003.
The division incurred an operating loss for the first time in many years of
#196,000 before exceptional items (2003: profit of #883,000).

Diffusion DX Air Conditioning sales grew strongly in its second year of
operation to #2.6 million (2003: #0.8 million for eight months trading). The
division incurred a reduced operating loss of #124,000 (2003: #258,000) as sales
moved further towards the projected sales targets.

Diffusion Air Treatment generated initial sales of Lifebreath products of
#182,000. The division incurred an operating loss of #338,000 due to start up
losses on Lifebreath, combined with engineering and development costs associated
with the Nightingale UVGI unit.

Central costs rose to #311,000 (2003: #256,000), due to the additional costs
incurred during the long-term illness of Stephen McNeice.

Exceptional redundancy costs were incurred by Diffusion Heating and Cooling of
#75,000 in the first quarter of the financial year.

An exceptional loss was incurred on the disposal of the Company's investment in
the shares of London and Boston Investments of #311,000.

Group cash flow

The group incurred a cash outflow of #869,000 (2003: inflow of #209,000) due
primarily to the operating losses incurred. Investment in stocks and debtors
increased due to the higher sales volumes achieved in the fourth quarter,
compared with the previous year. As a result of the cash outflow from operating
activities, capital expenditure was contained at #33,000 (2003: #142,000).

In February 2004, the Company sold its entire investment in the shares of London
and Boston Investments plc for #203,000, at a price of 4 pence per share. This
followed a prolonged period when the share price had been around or below the
price achieved.

The accounts include a pro-forma balance sheet at 31 March 2004, showing the
impact on the audited balance sheet as if the #3 million share placing proceeds
had been received on that date. This pro-forma balance sheet shows a net
positive bank position of #896,000.


Dividends

The Board does not recommend the payment of a dividend (2003: nil).


Operations
Diffusion Heating and Cooling ("Diffusion HC")

Diffusion HC experienced its worst year of trading for many years. The market
for fan coils and commercial heating products took a sudden and sharp downturn
in the first half of 2003 due to the uncertainty created by the global political
and economic situation at the time of the Iraq war. From a low point in the
first quarter of #1.524 million, sales subsequently recovered for the remainder
of the year to reach #8.0 million for the full year. This was significantly
down on the previous year's sales of #10.9 million.

As a result, for the first time in many years, Diffusion HC incurred an
operating loss of #196,000, before an exceptional charge for redundancies of
#75,000. A redundancy programme was completed in May 2003 involving 25 staff,
adjusting the cost base down to expected reduced sales volumes. The operating
loss was incurred in the first half year. Diffusion HC made a small profit in
the second half year on the increased sales volumes experienced. A dominant
feature of the current market place is the much shorter order lead times
demanded by contractors, which have adversely affected manufacturing
efficiencies due to the lateness in receiving final manufacturing instructions.

Diffusion HC's fan coils and heating products have continued to feature in many
prestigious office and hotel developments during the year, including The London
Stock Exchange, Scottish Parliament, Aspreys New Bond Street, Esso Glen Building
2, Standard Life, Lloyds TSB, HM Treasury, B & Q, and MBR Whitehall. The award
winning and patented Ambassador hotel fan coil unit gained further accolade from
the City Inn Westminster Hotel, where the external design team were successful
in winning the Best New Hotel Award at the recent European Hotel and Design
Conference 2003.

Diffusion HC continues to re- position itself by growing its commercial heating
product range, reducing reliance on fan coil sales. The commercial heating
product range is mid-way through an update programme and sales management
changes have been effected. The benefits of this strategy are expected to show
through in the latter part of the current financial year.


Diffusion DX Air Conditioning ("Diffusion DX")

Diffusion DX is now in its second year of operation and is becoming much more
established in the market place as a distributor of Panasonic and LG Electronics
packaged air conditioning equipment. This division continued to rapidly grow
during the year, with sales of #2.6 million, achieving excellent progress
towards reaching the annual sales targets set when the operation was first set
up in August 2002.

Diffusion DX moved into operating profit in the quarter ended 30 September 2003,
but incurred losses during the winter months, due to the traditionally seasonal
nature of the packaged air conditioning sector. Much marketing effort is being
directed towards larger value project led work, so as to reduce the seasonal
nature of this business.

The division's product offering was significantly enhanced in January 2004, when
Diffusion DX was granted distributor status for the Fujitsu range of packaged
air conditioning equipment. Diffusion DX is now in a strong position in the
market place as a distributor for three leading manufacturer's air conditioning
products. The Board is confident the addition of Fujitsu will enable
achievement of our objective for Diffusion DX to become one of the leading
distributors for the estimated #300 million UK market for packaged air
conditioning equipment.

Diffusion Air Treatment ("Diffusion AT")

The Diffusion AT division was formed in November 2003 to coordinate the Group's
activities in developing the air treatment and energy efficiency markets. This
division offers two product ranges:

* The Nightingale UVGI unit and NQ Environmental Inc's range of ultrab violet
products treat and sanitise air containing harmful airborne pathogens
such as TB, SARS and MRSA.

* The Lifebreath product range supplies fresh air ventilation to domestic homes
to manage the airtight construction methods required by new UK building
regulations.

Nightingale and NQ Environmental

In November 2002, the Company announced the prototype of its new Nightingale
unit and in April 2003 it won the Air Movement Product of The Year Award at the
2003 HVAC industry's H & V awards. During 2003, a second-generation production
model of the Nightingale unit was developed, and the accreditation test of this
production model, carried out at the Health Protection Agency, has now been
successfully completed.

The Group is in advanced discussions with a leading European manufacturer of air
handling plant to jointly develop a duct-mounted version of the Nightingale unit
and also to act as exclusive distributor of the Nightingale unit in Scandinavia.

The Board has identified the need to offer a wider range of products using ultra
violet technology in addition to the premium priced, high specification
Nightingale unit. The Group has therefore entered into an exclusive
distribution agreement with the American company, NQ Environmental Inc., to
distribute a complete range of low to medium specification ultra violet air
treatment products in the UK and elsewhere in the European Union. NQ
Environmental has supplied its products to approximately 700 hospitals,
predominantly in the USA and Canada and has a distribution agreement with Owens
and Minor Inc, the largest US medical equipment distribution company, to
distribute products throughout the USA.

NQ has been granted a period of exclusivity to 30 September 2004, to enable it
to explore opportunities for marketing the Nightingale unit in the US and
Canadian markets. The Nightingale was exhibited by NQ at a commercial trade
show in the USA in June where interest was very encouraging. The initial sale
in the USA of product using Nightingale technology was achieved in July 2004 to
the Northwest Hospital Center in Randallstown, Maryland.

Lifebreath

The Group has established an exclusive agreement with the Canadian company,
Nutech, to distribute its Lifebreath range of products in the UK, and elsewhere
in the European Union and Switzerland. Lifebreath products are filtration and
heat recovery systems targeted primarily at the domestic home market. The
products are capable of complying with building regulations by providing fresh
air ventilation (helpful for asthma, hay fever and other allergies caused by
poor air quality) to offset airtight construction methods and at the same time
recovering up to approximately 70% of normal heating energy loss.

The first Lifebreath sales in the UK were made in the year ended 31 March 2003.
A sales team has now been recruited and prospects for rapid growth are
excellent.

Directors

Robert Unsworth was re-appointed to the Board on 1 July 2003 as an executive
director, responsible for finance and company secretarial matters whilst Stephen
McNeice remains on long term sick leave. The Board wishes him a speedy
recovery.

Management and employees

On behalf of the Board, I should like to thank all employees for their continued
hard work, loyalty and commitment during the difficult trading conditions last
year.

Graham R Mackenzie
Chairman


Group profit and loss account
for the year ended 31 March 2004
2004 2003
Note #000 #000

Turnover 3 10,819 11,704
Cost of sales (8,508) (7,884)

Gross profit 2,311 3,820
Distribution costs (2,466) (2,388)
Administrative expenses (889) (1,063)


Operating (loss)/profit
Before exceptional items 3 (969) 369
Exceptional items 4 (75) -

(Loss)/profit before interest (1,044) 369
Loss on disposal of fixed asset investment 4 (311) -
Interest payable (117) (106)

(Loss)/profit on ordinary activities before taxation (1,472) 263

Tax on (loss)/profit on ordinary activities - -

(Loss)/profit for the financial year (1,472) 263
Dividends on equity shares - -

Transfer (from)/to reserves (1,472) 263

Earnings/(loss) per share:
Basic 5 (2.01)p 0.36p
Diluted 5 (2.01)p 0.31p
Before exceptional items 5 (1.48)p 0.36p

Both the turnover and operating results shown above are entirely in respect of
continuing operations.

There are no other recognised gains or losses other than as recorded in the
profit and loss account for the year.


Group balance sheet
At 31 March 2004 31 March 31 March
2004 2003
#000 #000
Fixed assets
Intangible assets 17 -
Tangible assets 317 401
Investments - 514
334 915
Current assets
Stocks 1,323 1,040
Debtors 2,654 2,153
Cash at bank - 186
3,977 3,379
Creditors - amounts falling due within one year (4,515) (2,949)

Net current (liabilities)/assets (538) 430

Total assets less current liabilities (204) 1,345

Creditors - amounts falling due after more than one year (7) (129)

(211) 1,216

Capital and reserves
Called up share capital 746 731
Share premium account 1,587 1,557
Other reserves 7,449 7,449
Profit and loss account (9,993) (8,521)

Equity shareholders' funds (211) 1,216

Note:

The group was re-financed with a #3 million share placing completed on 30 April
2004. A pro-forma balance sheet showing the impact of this share placing at 31
March 2004 is set out on page 12.


Reconciliation of movements in shareholders' funds
For the year ended 31 March 2004

Group
2004 2003
#000 #000

(Loss)/profit for the year (1,472) 263
Issue of ordinary shares 15 -
Increase in share premium account 30 -

Movements in shareholders' funds (1,427) 263

Shareholders' funds at beginning of year 1,216 953

Shareholders' funds at end of year (211) 1,216



Group cash flow statement 2004 2003
For the year ended 31 March 2004
#000 #000

Cash (outflow)/inflow from operating (905) 487
activities
Returns on investment and servicing of (117) (106)
finance
Capital expenditure and financial investment (33) (142)
Expenditure on intangible assets (17) (30)
Disposal of shares in London & Boston
Investments plc 203 -

Cash (outflow)/inflow before financing (869) 209
Financing:
Issue of share capital 45 -
Increase in debt 638 14
(Reduction)/increase in cash during year (186) 223


Reconciliation of net cash flow to movement in net debt
2004 2003
#000 #000

(Reduction)/increase in cash in year (186) 223
Increase in debt (638) (14)

Change in net debt resulting from cash flows (824) 209
New finance leases - (26)

(Increase)/reduction in net debt (824) 183
Net debt at start of year (947) (1,130)

Net debt at end of year (1,771) (947)


Reconciliation of operating profit to operating cash flows

2004 2003
#000 #000
Operating (loss)/profit before exceptional (969) 369
items
Exceptional items (75) -

Operating (loss)/profit after exceptional (1,044) 369
items
Depreciation and amortisation 117 149
Stocks (283) (316)
Debtors (501) 487
Creditors 806 (202)
(905) 487

Notes to the accounts

1. Accounting policies

The financial information set out above has been prepared using accounting
policies consistent with 2003.

2. Basis of preparation

The financial information for the year ended 31 March 2004 and 2003 set out
above does not constitute statutory accounts within the meaning of section 240
of the Companies Act 1985. The information has been extracted from the
statutory accounts of Energy Technique plc for the year ended 31 March 2004,
which have not yet been filed with the Registrar of Companies. Statutory
accounts for the year ended 31 March 2003 have been delivered to the Registrar
of Companies. Statutory accounts for the year ended 31 March 2004 were approved
by the Board of Directors on 20 July 2004, are audited and will be delivered to
the Registrar of Companies following the Annual General Meeting on 6 October
2004.

The Company's auditors, Milsted Langdon, have reported on the 2004 and 2003
accounts under section 235(1) of the Companies Act 1985. Those reports were not
qualified within the meaning of section 235(2) of the Companies Act 1985 and did
not contain statements made under section 237(2) and 237(3) of the Companies Act
1985.

3. Segmental analysis

Turnover Operating profit/ Operating net
(loss) assets
2004 2003 2004 2003 2004 2003
#000 #000 #000 #000 #000 #000
Diffusion Heating and Cooling

Before exceptional items 7,994 10,930 (196) 883 - -
Redundancy costs - - (75) - - -

After exceptional items 7,994 10,930 (271) 883 1,130 1,409
Diffusion DX Air Conditioning 2,643 774 (124) (258) 476 326
Diffusion Air Treatment 182 - (338) - 37 -
Central and Plc costs

Before exceptional items - - (311) (256) - -
Sale of unlisted investment - - (311) - - -

After exceptional items - - (622) (256) (83) 428
10,819 11,704 (1,355) 369 1,560 2,163

Borrowings (1,771) (947)
Taxation - -
(211) 1,216

4. Exceptional items
2004 2003
#000 #000
Operating items
Redundancies and employee termination costs 75 -
Loss on disposal of shares in London and Boston Investments plc 311 -
386 -

The exceptional items have been classified as follows:
Cost of sales 75 -
Loss on disposal of fixed asset investment 311 -
386 -
The tax effect of exceptional items is to increase trading and capital losses
carried forward.

5. (Loss)/earnings per share

The (loss)/earnings per share calculations have been arrived at by reference to
the following earnings and weighted average number of shares in issue during the
year.
2004 2003
#000 #000
Basic
(Loss)/profit after tax (1,472) 263

Before exceptional items
Operating (loss)/profit (969) 369
Interest payable (117) (106)
Tax payable - -

(Loss)/profit after tax (1,086) 263

No. No.
Weighted average number of shares in issue 73,337,751 73,075,456
Weighted average number of shares on a diluted basis 83,612,779 84,828,723

Supplementary basic (loss)/earnings per share have been calculated to exclude
the effect of redundancy costs and the loss on the disposal of the Company's
investment in the shares of London and Boston Investments plc.

6. Posting of Report and Accounts

The 2004 Report and Accounts will be posted to shareholders on 28 July 2004.

Contacts:

Allan Piper, First City Financial Public Relations: 020 7436 7486
07050 203304

Graham Mackenzie, Chairman, Energy Technique plc: 07901 550577

Leigh Stimpson, Managing Director, Energy Technique plc: 07919 214882

Rob Unsworth, Finance Director, Energy Technique plc: 020 8783 0033


Pro-forma balance sheet
At 31 March 2004
31 March Adjustment for 31 March
2004 Share 2004
Audited Placing Pro-forma
#000 #000 #000
Fixed assets
Intangible assets 17 - 17
Tangible assets 317 - 317
334 - 334
Current assets
Stocks 1,323 - 1,323
Debtors 2,654 - 2,654
Cash at bank - 928 928
3,977 928 4,905
Creditors - amounts falling due within one year
Borrowings (1,764) 1,739 (25)
Other creditors (2,751) - (2,751)
(4,515) 1,739 (2,776)
Net current (liabilities)/assets (538) 2,667 2,129
Total assets less current liabilities (204) 2,667 2,463
Creditors - amounts falling due after more than one year
Borrowings (7) - (7)

(211) 2,667 2,456

Capital and reserves
Called up share capital 746 750 1,496
Share premium account 1,587 1,917 3,504
Other reserves 7,449 - 7,449
Profit and loss account (9,993) - (9,993)

Equity shareholders' funds (211) 2,667 2,456


The pro-forma balance sheet shown above has been extracted from the audited
balance sheet at 31 March 2004, adjusted only for the impact of the #3 million
share placing completed on 30 April 2004, net of estimated costs of #333,000.
No adjustments have been made for trading since 31 March 2004 or for any other
adjustments.


This information is provided by RNS
The company news service from the London Stock Exchange
END

TA (Technical Analyis is looking good after today's close at these prices) :

Investtech Analysis after today's close :

Positive Candidate (Short term) - Jul 26, 2004
Is within an approximate horizontal trend, which indicates further development in the same direction. The stock has support at p 4.30 and resistance at p 8.00. Volume tops and volume bottoms correspond well with tops and bottoms in the price. This strengthens the stock and increases the chance of a break up. Trading volume has increased substantially lately. This shows there is an increased interest for the stock, possibly because of fundamental news. The stock is overall assessed as technically positive for the short term.

Positive Candidate (Medium term) - Jul 26, 2004
ENERGY TECH. ORD 1P has broken the falling trend and reacted strongly up. For the time being, it is difficult to say anything about the future trend direction. The stock has resistance at p 8.70. The RSI curve shows a rising trend, which could be an early signal for the start of a rising trend. The stock is overall assessed as technically positive for the medium long term.

Neutral (Long term) - Jul 26, 2004
Has broken the falling trend down, which indicates an even stronger falling rate. Has reacted back after the break of the inverse head and shoulders formation. There is support around 3.79, which now indicates good buying opportunities. An established break through this support will neutralize the positive signal. The stock has support at p 2.70 and resistance at p 11.20. Volume tops correspond well with price tops, and volume bottoms correspond well with price bottoms. Volume balance is also positive, which weakens the falling trend and could be an early signal for a coming trend break. Trading volume has increased substantially lately, which may be because of fundamental news. The stock is overall assessed as technically neutral for the long term.

Promising :

---------The RSI curve shows a rising trend, which could be an early signal for the start of a rising trend.

---------Volume balance is also positive (i.e. more buying than selling), which weakens the falling trend and could be an early signal for a coming trend break.

Mrs Ewing your doing your best to pump this stock,you must be in at double figures id imagine.

Downtrend lately....sob sob!

I used to have these but sold at good profit (fortunately)

now its `ring a ring a roses, atishoo atishoo etc`

I had been monitoring these this week as I mentioned and I think the price has bottomed out today. I bought in this morning at 4.95 pence. The selling has virtually dried up now. Why I say the price has bottomed out now is because buyers came in heavily today when the offer price hit 5.00 pence today and the same thing happened yesterday when the offer price hit 5.25 pence. There has been no sizeable sells in terms of more than 100K, whereas the buying has been good over the last week in terms of size ie. a 200,000 buy was reported as delayed at 5.00 pence and a 500,000 T buy came through at 5.00 pence in the afternoon session. The latter was worked through the day and came through in the afternoon. Level 2 closed very strong, the best it can get at 3 v 1. The potential downside is to 4 pence whereas the upside potential is huge from these levels.

Price closed at 4.75-5.50 pence.

Sue very little buying today when the offer was raised above 5p. Still a little profit taking to be worked through.Expect the price to resume uptrend sometime tomorrow. Was hoping the Nas would not rally, as i expect an early mark up which the price may rally from.Missed the boat today at 4.89p b****** phone, may have cost me a few bucks if i have to pay 5.25p or above tomorrow.,as i expect the sp to be 6p or above by early next week.

Hi momentum, thanks for your input.

Contrary to what is published in the buy/sell columns : the actual buy and sell figures were :

Buys - 1,336,349
Sells - 1,540,645
Rollover trades - 200,000.

Buys and Sells nearly equated to the same amounts for the first time in the last seven trading days.

Night!

SH take a look at FAR but be quick.

Hi suehelen had to pay 5.5p today. Thankx some good post today on III today.
Looks like when resistance at 5.5p is overcome we could have some good upside to test the previous high. Not tempted into CMS at the moment ?, im very bearish (chart looking dead )possible further downgrading of contracts that were expected to be signed.

Hi momentum, that was still a good price.

We finished with a shooting star (see below candlesticks chart) on the candlesticks for today which is a bullish signal. Buyers came back today and the selling appears to finish as re: my post yesterday but today the buys outnumbered the sells (see trades page). Price finishing up 4.90% today to 5.00-5.75 though the real spread seemed to be about 5.10-5.50 pence. Level 2 closing at 3 v 1 which is the strongest it can get for the second day running. I expect another blue day tomorrow.



Stars make up part of four separate reversal patterns:

Morning Star

Evening Star

Doji Star

Shooting Star (Inverted Hammer)

Shooting Star -- a small real body near the lower end of the trading range, with a long upper shadow. The color of the body is not critical. Not usually considered a major reversal sign, only a warning.

http://www.tradersedgeindia.com/candlestick.htm

Memo from Graham Mackenzie below : reply to an email sent.

Thank you for your e mail comments.

I would respond to your comments as follows.

The ETQ share price has fallen back slightly in the past few days because there has been heavy selling of shares because of profit taking by certain investors who took up stock in the recent placing, and because one major shareholder from the original consortium that bought in to ETQ three years ago, Harrel Hospitality has sold its complete holding in the company in order we believe to finance a hotel purchase.That sales have resulted in great liquidity in the stock.

As regards the marketing of Nightingale you should not forget that this is a sophisticated product selling for 6000 to 8500 pounds depending on the spec.. This is not a consumer sale so our marketing is directed at NHS Trusts and the private hospital groups such as BUPA. Any consumer or media coverage is peripheral to the main marketing effort where, for example, ETQ has made presentations to two major NHS Infection Control conferences in the last few weeks.

You can be assured that every hospital Chief exec and infection control director in the NHS has been made aware of Nightingale.

The problem is the bureaucratic morass of NHS purchasing procedures which delay the procurement process endlessly.

Why don't you tackle your local MP about the general comments you make about infection control in the NHS? We stand willing to supply Nightingale and have ensured that we have several in stock for immediate delivery should a hospital break out of its red tape and order one.

Regards
Graham Mackenzie

This is a link to one of the presentations he mentioned.

http://www.otjonline.com/download/june04.pdf (page 14)

and also this:

http://www.otjonline.com/download/may04.pdf (page 12)

On 28 April 2004, Joseph Tufo, Managing Director of UVGI Systems
Ltd. gave a presentation to 160 delegates at the Tackling Infection
Control conference held at the Copthorne Tara Hotel in London.
Participating in the conference was leading infection control
specialists, consultant microbiologists and clinical governance
managers from across the UK.
Mr. Tufo presented on the importance of air quality in the built
environment and explained how technology has advanced from simple
HEPA fi lters to products such as UVGIs Nightingale unit which draws
in air and includes four primary levels of protection including HEPA
fi lters plus a decontaminating section containing two banks of four
low-pressure UV lamps, located outside the airstream behind quartz
screens. Mr. Tufo described the problems associated with airborne
microbials and how UV treatment can sanitise bacteria.
Kathy Lee, an Acute Medical Ward Sister with over 30 years experience
in the NHS, then discussed treatment of immuno-compromised and
infectious patients, including a case study at North Hampshire hospital,
Basingstoke on using Nightingale to create a positive pressure room
and similar experience in handling SARS at a Toronto Hospital with
negative pressurisation. In these studies, another advantage of the
Nightingale system was the added benefi t of being highly mobile.
Other presentations at the conference included Nigel Tomlinson,
Principal Scientifi c Advisor, Centre for Healthcare Engineering, NHS
Estates who stated that early tests by NHS Estates had indicated the
positive results shown by UV treatment of airborne antimicrobials and
the likely recommendation from NHS Estates as to the use of such UV
fi ltering systems in hospitals.
Different forms of tackling control were also described at the
conference including a presentation from Julie Storr, Assistant Director
of Safety Solutions, NPSA who talked about the NHS clean your
hands campaign to encourage patients to ask nursing and medical
staff if they has cleansed their hands prior to treatment.
Other topics discussed included understanding the impact of the NHS
Winning Ways directive. Dr Louise Teare, Director of Infection Control
and Consultant Microbiologist at Mid-Essex Hospital Services NHS
Trust described interpreting the infection control timetable and what is
required including integrating infection control with clinical governance
and care planning.
The fi rst multi-parameter test - Cardiac Risk
- tests for total cholesterol, HDL, LDL and
triglycerides. The Cardiac Risk test identifi es
and monitors patients at risk of developing
Coronary Heart Disease (CHD), the leading
cause of death in North America and Europe.
Additional strips under development include
tests for renal, liver and metabolic functions.
For further information please contact:
Will Col, Oxford Biosensors Ltd,
Oxford Industrial Park, Mead Road,
Yarnton, Oxfordshire OX5 1QU.
Tel: 01865 849100. Fax: 01865 849200.
email: will.collon@Oxford-Biosensors.com
Website: www.Oxford-Biosensors.com
When responding to adverts please quote OTJ
The presenters informed the audience about the methods for tackling
infection and how to comply with current NHS legislation and guidelines.
The Chief Medical Offi cers publication of Winning Ways in December
2003 put the onus for effective infection control fi rmly onto the senior
management of acute trusts. Without improved infection control,
hospitals star ratings will be affected, the patient experience will be
compromised, billions of pounds may be squandered and thousands of
lives could be lost.
The strong line-up of speakers helped to address issues of infection
control, clinical governance and the Winning Ways directive as well as
tackling crucial questions of accountability, risk management and how to
carry out increased surveillance and reporting requirements, as well as
those of staffi ng and resourcing change.
For further information please contact:
Joseph Tufo, UVGI Ltd
Telephone: 01256 814162 joe@uvgi.co.uk
Joseph Tufo and Kathy Lee present at the Tackling Infection Control
meeting in London.
Tackling infection control is the priority for UVGI

UVGI Ltd. have jointly sponsored a meeting entitled Redesigning
Chronic Disease Management which was held on 25th May at the
Sheraton Park Lane Hotel, London. The one-day conference included a
keynote lecture from Sir Liam Donaldson, Chief Medical Offi cer.
The subject of chronic disease management is of major signifi cance to
UVGI who manufacture Nightingale, a new environmental disinfection
method that uses ultraviolet light to tackle the problem of hospitalbased
pathogens. The Nightingale is the fi rst ever British mobile air
sanitisation system with the ability to provide positive or negative
room pressurisation in line with CDC and NHS guidelines.
The UVGI sponsored meeting was specifi cally designed for Primary
Care Trusts. The conference addressed the overall issue of the
management of Chronic Medical conditions, specifi cally concentrating
on the practicalities of implementing a coordinated approach.
With the introduction of new initiatives, including the Expert Patient
Programme, hospitals now recognise the opportunity to make a
signifi cant change to the care and management of chronic disease.
Some of the crucial issues that were covered included how to learn
lessons from the US on case management of chronic disease, training
and development of staff to avoid unnecessary hospital admissions
and taking a whole systems approach to redesigning chronic disease
management.
Chronic diseases can affect as many as 17.5 million adults in the
UK and represent a huge and increasing burden on NHS resources.
International experience has shown that better integration between
primary, secondary and social care can reduce hospitalisation and yet
provide better care for patients. PCTs are in the ideal position to bridge
the gap and plan for integrated care. In order to meet this challenge
services will need to be replanned and redesigned to give a more
coordinated, responsive and integrated approach.
Speakers, including Sir Liam Donaldson, Chief Medical Offi cer and
Gary Belfi eld, Head of Primary Care and Policy for Chronic Disease,
Department of Health, discussed experiences including patient selfmanagement
programmes, the development of staff skills, multi-agency
integrated working and preventative measures to avoid unnecessary
and inappropriate hospital admissions. The authoritative panel of
speakers described the different models of care available, giving the
audience the opportunity to update on the latest trends taking place
nationwide and receive advice on how to take forward current systems
and procedures.
A panel discussion and Q&A sessions gave an excellent opportunity
to question experts and share views. The audience numbered 260
with delegates working in Nursing, Operations, Intermediate Care,
Commissioning, Clinical Leads as well as those involved in the
planning, commissioning and delivery of chronic disease management
services.
For further information please contact: Joseph Tufo UVGI Ltd
Telephone: 01256 814162 E-mail: joe@uvgi.co.uk
UVGI sponsor

Further : They mention UVGI rather than ETQ in the above but it is ETQ's presentation promoting UVGI.

In the second one there was a reference to an NHS Estates chap who really liked it and was going to recommend to the Trusts that they take up UV.

Some good news out today :

Evolution Beeson Gregory (Evo) have upgraded Energy Technique (ETQ) from Overweight to BUY!! It was on Bloomberg.

That explains why EVO moved from the offer to the bid on Level 2 and were actively bidding for stock.

Evolution Beeson Gregory Website :

Don't think we can get in though as if one selects private individual then the registration doesn't seem to complete.

http://www.evbgresearch.com/

The last candle in post 122 in in fact a doji and a bearish doji at that


macd is definitely not positive. Anyone thinking of buying should wait to see if there is a bounce off 4p with strong positive volume